Clomiphene Citrate Medication for Infertility and Risk of Stillbirth or Neonatal Death: A Population-based Cohort Study
Main finding · Perinatal death (singletons)Result — go to the resultOdds ratio 1.54 95% CI 1.15–2.07Authors' conclusion
Risk of perinatal death may be increased in pregnancies that follow use of CC. While established confounding factors related to infertility were taken into account, there may be some residual contribution of underlying infertility.
Study context
- Population
- All women giving birth (births ≥20 weeks) between July 2003 and December 2015, South Australia
- Participants
- 242,077 women
- Exposure
- Clomiphene citrate (CC) exposure vs no CC exposure
- Outcome
- Perinatal death: stillbirths and neonatal deaths (within 28 days of birth) combined
Methodological detailswhole of population data linkage
- Whole of population data linkage
Main finding
Perinatal death (singletons)
Odds ratio
1.54
95% CI 1.15–2.07
CCvs Unexposed
OR 1.54 (95% CI 1.15–2.07)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Stillbirth and neonatal death prevalence (singletons)
- Stillbirth, all singletons
- 6.6 per 1000 births
- Neonatal death, all singletons
- 2.1 per 1000 live births
- Stillbirth, singletons conceived with CC
- 10.2 per 1000
- Neonatal death, singletons conceived with CC
- 3.1 per 1000
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Clomiphene Citrate Medication for Infertility and Risk of Stillbirth or Neonatal Death: A Population-based Cohort Study. J Clin Endocrinol Metab. Published 22 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →